JPMorgan lowered the firm’s price target on PTC Therapeutics to $51 from $53 and keeps an Overweight rating on the shares. The company’s Q2 results were largely in line with expectations, the analyst tells investors in a research note. The firm continues to view PTC shares at an attractive entry point into “multiple near-term value-accretive catalysts.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Q2 Financial Performance and Updates Webinar
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Is PTCT a Buy, Before Earnings?
- PTC Therapeutics submits sepiapterin NDA to U.S. FDA
- Truist healthcare analyst holds an analyst/industry conference call